Denosumab in osteoporosis

Expert Opinion on Drug Safety

Volumn 13, Issue 2, 2014, Pages 247-253

  Diab, Dima L ^a   Watts, Nelson B ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b Mercy Health Osteoporosis and Bone Health Services   (United States)

Author keywords

Denosumab; Efficacy; Fractures; Osteoporosis; Safety

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB;

ARTICLE; BONE DENSITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FEMUR FRACTURE; HIP FRACTURE; HUMAN; HYPOCALCEMIA; INFECTION; JAW OSTEONECROSIS; NEOPLASM; OSTEOLYSIS; OSTEOPOROSIS; SKIN MANIFESTATION; SPINE FRACTURE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; FRACTURES, BONE; HUMANS; OSTEOPOROSIS;

EID: 84892697088     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.860133     Document Type: Article

References (47)

1. Highlights of prescribing information. Prolia (denosumab) Available from: http://pi.amgen.com/united-states/prolia/ prolia-pi.pdf [Last accessed 26 May 2013]
2. Block GA, Bone HG, Fang L, et al. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 2012;27:1471-9
3. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65
4. Papapoulos S, Chapurlat R, Libanati C, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 2012;27:694-701
5. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009;24: 153-61
6. Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010;25: 72-81
7. Boonen S, Adachi JD, Man Z, et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2011;96:1727-36
8. McClung MR, Boonen S, Torring O, et al. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res 2012;27:211-18
9. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008;26: 4875-82
10. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361: 745-55
11. Orwoll E, Teglbjaerg CS, Langdahl BL, et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 2012;97:3161-9
12. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397: 315-23
13. Watts NB, Roux C, Modlin JF, et al. Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? Osteoporos Int 2012;23:327-37
14. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377: 813-22
15. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29: 1125-32
16. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28: 5132-9
17. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12: 1260-8
18. Morony S, Tintut Y, Zhang Z, et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation 2008;117: 411-20
19. Helas S, Goettsch C, Schoppet M, et al. Inhibition of receptor activator of NFkappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol 2009;175: 473-8
20. Janda K, Krzanowski M, Chowaniec E, et al. Osteoprotegerin as a marker of cardiovascular risk in patients on peritoneal dialysis. Pol Arch Med Wewn 2013;123: 149-55
21. Augoulea A, Vrachnis N, Lambrinoudaki I, et al. Osteoprotegerin as a marker of atherosclerosis in diabetic patients. Int J Endocrinol 2013;2013:182060
22. Mogelvang R, Haahr-Pedersen S, Bjerre M, et al. Osteoprotegerin improves risk detection by traditional cardiovascular risk factors and hsCRP. Heart 2013;99: 106-10
23. Montagnana M, Lippi G, Danese E, Guidi GC. The role of osteoprotegerin in cardiovascular disease. Ann Med 2013;45: 254-64
24. Giaginis C, Papadopouli A, Zira A, et al. Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor kappaB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis. Med Sci Monit 2012;18:CR597-604
25. Tousoulis D, Siasos G, Maniatis K, et al. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease. Int J Cardiol 2013;167(5): 1924-8
26. Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004;109: 2175-80
27. Martin-Baez IM, Blanco-Garcia R, Alonso-Suarez M, et al. Severe hypocalcaemia post-denosumab. Nefrologia 2013;33: 614-15
28. McLachlan JM, Marx GM, Bridgman M. Severe symptomatic hypocalcaemia following a single dose of denosumab. Med J Aust 2013;199: 242-3
29. Okada N, Kawazoe K, Teraoka K, et al. Identification of the risk factors associated with hypocalcemia induced by denosumab. Biol Pharm Bull 2013;36(10): 1622-6
30. Ungprasert P, Cheungpasitporn W, Srivali N, et al. Life-threatening hypocalcemia associated with denosumab in a patient with moderate renal insufficiency. Am J Emerg Med 2013;31:756e1-2
31. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91
32. Reid IR, Miller PD, Brown JP, et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 2010;25:2256-65
33. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 2011;96:972-80
34. Eastell R, Christiansen C, Grauer A, et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 2011;26: 530-7
35. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25: 2267-94
36. Shane E, Ebeling PR, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American society for bone and mineral research. J Bone Miner Res 2013;doi: 10.1002/jbmr.1998
37. Available from: http://www.mhra.gov.uk/ Safetyinformation/ DrugSafetyUpdate/ CON239411 [Last accessed 12 June 2013]
38. Paparodis R, Buehring B, Pelley E, Binkley N. A Case of an Unusual Subtrochanteric Fracture in a Patient Receiving Denosumab. Endocr Pract 2013;19(3):e64-8
39. Adami S, Libanati C, Boonen S, et al. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. J Bone Joint Surg Am 2012;94: 2113-19
40. Jamal SA, Ljunggren O, Stehman-Breen C, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 2011;26: 1829-35
41. Brown JP, Roux C, Torring O, et al. Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial. J Bone Miner Res 2013;28:746-52
42. Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 2013;382:50-6
43. Kendler DL, McClung MR, Freemantle N, et al. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int 2011;22: 1725-35
44. Freemantle N, Satram-Hoang S, Tang ET, et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24- month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 2012;23: 317-26
45. Jonsson B, Strom O, Eisman JA, et al. Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 2011;22: 967-82
46. Hiligsmann M, Boonen A, Dirksen CD, et al. Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women. Expert Rev Pharmacoecon Outcomes Res 2013;13: 19-28
47. Hiligsmann M, Reginster JY. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. Pharmacoeconomics 2011;29: 895-911